Vistagen Therapeutics, Inc. (VTGN)
| Market Cap | 25.00M -62.7% |
| Revenue (ttm) | 789,000 +13.0% |
| Net Income | -67.05M |
| EPS | -1.89 |
| Shares Out | 39.62M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 325,989 |
| Open | 0.6450 |
| Previous Close | 0.6333 |
| Day's Range | 0.6202 - 0.6635 |
| 52-Week Range | 0.4300 - 5.1400 |
| Beta | 0.30 |
| Analysts | Hold |
| Price Target | 0.97 (+53.72%) |
| Earnings Date | Jun 16, 2026 |
About VTGN
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company’s product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial to treat major depressive disorder. It also devel... [Read more]
Financial Performance
In fiscal year 2025, Vistagen Therapeutics's revenue was $486,000, a decrease of -54.32% compared to the previous year's $1.06 million. Losses were -$51.42 million, 75.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for VTGN stock is "Hold." The 12-month stock price target is $0.97, which is an increase of 53.72% from the latest price.
News
Vistagen to Participate in Jefferies 2026 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen to Participate in Jefferies 2026 Global Healthcare Conference.
Vistagen Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026
The session highlighted advances in intranasal neuroscience candidates, with fasedienol leading in SAD treatment and key phase III data for PALISADE-4 expected soon. Pipeline assets itruvone and refisolone show promise in MDD and menopausal hot flashes, with cash runway into 2027.
Vistagen appoints Angelov as Chief Medical Officer
Vistagen (VTGN) announced the appointment of Angel Angelov, MD, MBA, as Chief Medical Officer, CMO, effective May 18, 2026. Dr. Angelov most recently served as CMO at Theranica Published first…
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen, a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new cla...
Vistagen reports preliminary positive data on ongoing PALISADE-3 study
Vistagen (VTGN) announced preliminary positive data from the ongoing open-label extension portion of its PALISADE-3 Phase 3 study of fasedienol for the acute treatment of social anxiety disorder. In a...
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
Vistagen announces completion of last patient visit in PALISADE-4 study
Vistagen (VTGN) announced that the last patient has completed the last visit in the randomized, double-blind, placebo-controlled portion of PALISADE-4, the Company’s Phase 3 clinical trial evaluating ...
Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
AbCellera target is profile more attractive than Vistagen, says JonesResearch
JonesResearch notes that Vistagen (VTGN) received an FDA “Study May Proceed” letter enabling further Phase 2 development of intranasal refisolone for menopausal vasomotor symptoms, also known as hot f...
Vistagen receives FDA ‘Study May Proceed’ letter under refisolone IND filing
Vistagen (VTGN) announced receipt of a “Study May Proceed” letter from the U.S. Food and Drug Administration under its U.S. Investigational New Drug application for refisolone nasal spray, the Company...
Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
Vistagen Therapeutics Transcript: Stifel 2026 Virtual CNS Forum
Fasedienol is advancing in phase III for social anxiety disorder, with PALISADE-4 results expected in the first half of the year. AI-driven analytics and operational improvements are being applied to enhance trial outcomes, while a robust data package and additional pipeline assets support future regulatory and clinical milestones.
Vistagen to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
Vistagen Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
The conference highlighted a pipeline of non-systemic, intranasal drug candidates targeting large unmet needs in neuropsychiatry and women's health. Lead asset Fasedienol showed positive phase III results in social anxiety disorder, with further pivotal data expected in H1 2026. AI-driven trial optimization and multiple regulatory strategies are being pursued.
Vistagen Facing Class Action over Social Anxiety Disorder Drug Claims
A class action lawsuit was filed against Vistagen Therapeutics ($VTGN) on January 15, 2026. Plaintiffs in the federal securities class action allege that they acquired Vistagen stock at artificially i...
Vistagen to Participate in the 46th Annual TD Cowen Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
Vistagen Therapeutics Earnings Call Transcript: Q3 2026
Completed PALISADE-3 and advanced PALISADE-4 with operational refinements and AI-driven analytics. Cash position at $61.8M as of December 31, 2025, with ongoing cash preservation. IND for rafisolone planned for H1 2026.
Vistagen Therapeutics Quarterly report: Q3 2026
Vistagen Therapeutics has published its Q3 2026 quarterly earnings report on February 12, 2026.
Vistagen Therapeutics Earnings release: Q3 2026
Vistagen Therapeutics released its Q3 2026 earnings on February 12, 2026, summarizing the period's financial results.
Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
VTGN Investors Encouraged to Seek Lead Plaintiff Role in Vistagen Therapeutics Securities Class Actoin Case with Johnson Fistel
SAN DIEGO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Vistagen Therapeutics,...
Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) DEADLINE ALERT – Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline
NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Vistagen Therapeutics, Inc. (NASDAQ: VTGN)? Did you purchase your shares between April 1, 2024 and...
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) INVESTOR ALERT Investors With Large Losses in Vistagen Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquir...